GB9807639D0 - Anti-inflammatory agents - Google Patents

Anti-inflammatory agents

Info

Publication number
GB9807639D0
GB9807639D0 GBGB9807639.1A GB9807639A GB9807639D0 GB 9807639 D0 GB9807639 D0 GB 9807639D0 GB 9807639 A GB9807639 A GB 9807639A GB 9807639 D0 GB9807639 D0 GB 9807639D0
Authority
GB
United Kingdom
Prior art keywords
cannabinoids
inflammatory agents
inflammatory diseases
treating inflammatory
cannabidiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9807639.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Hebrew University of Jerusalem HUJI
Original Assignee
Kennedy Institute of Rheumotology
Mathilda and Terence Kennedy Institute of Rheumatology
Hebrew University of Jerusalem HUJI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology, Mathilda and Terence Kennedy Institute of Rheumatology, Hebrew University of Jerusalem HUJI filed Critical Kennedy Institute of Rheumotology
Priority to GBGB9807639.1A priority Critical patent/GB9807639D0/en
Publication of GB9807639D0 publication Critical patent/GB9807639D0/en
Priority to JP2000543134A priority patent/JP2002511411A/ja
Priority to PCT/GB1999/001140 priority patent/WO1999052524A1/en
Priority to AU34361/99A priority patent/AU757945B2/en
Priority to EP99915942A priority patent/EP1071417B1/en
Priority to ES99915942T priority patent/ES2241277T3/es
Priority to CA002328368A priority patent/CA2328368C/en
Priority to IL13897999A priority patent/IL138979A0/xx
Priority to DK99915942T priority patent/DK1071417T3/da
Priority to US09/673,207 priority patent/US6410588B1/en
Priority to AT99915942T priority patent/ATE288749T1/de
Priority to DE69923671T priority patent/DE69923671T2/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB9807639.1A 1998-04-14 1998-04-14 Anti-inflammatory agents Ceased GB9807639D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
DE69923671T DE69923671T2 (de) 1998-04-14 1999-04-14 Verwendung von cannabidiol als entzündunghemmende mittel
EP99915942A EP1071417B1 (en) 1998-04-14 1999-04-14 Use of cannabidiol as anti-inflammatory agent
PCT/GB1999/001140 WO1999052524A1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents
AU34361/99A AU757945B2 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents
JP2000543134A JP2002511411A (ja) 1998-04-14 1999-04-14 抗炎症剤
ES99915942T ES2241277T3 (es) 1998-04-14 1999-04-14 Uso de canabinoides como agentes anti-inflamatoprios.
CA002328368A CA2328368C (en) 1998-04-14 1999-04-14 Anti-inflammatory agents
IL13897999A IL138979A0 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents
DK99915942T DK1071417T3 (da) 1998-04-14 1999-04-14 Anvendelse af cannabidiol som anti-inflammatorisk middel
US09/673,207 US6410588B1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents
AT99915942T ATE288749T1 (de) 1998-04-14 1999-04-14 Verwendung von kannabidiol als entzündunghemmende mittel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
GB9807639D0 true GB9807639D0 (en) 1998-06-10

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9807639.1A Ceased GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents

Country Status (12)

Country Link
US (1) US6410588B1 (https=)
EP (1) EP1071417B1 (https=)
JP (1) JP2002511411A (https=)
AT (1) ATE288749T1 (https=)
AU (1) AU757945B2 (https=)
CA (1) CA2328368C (https=)
DE (1) DE69923671T2 (https=)
DK (1) DK1071417T3 (https=)
ES (1) ES2241277T3 (https=)
GB (1) GB9807639D0 (https=)
IL (1) IL138979A0 (https=)
WO (1) WO1999052524A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
AU3910700A (en) 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
EP1206934A1 (en) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade of sodium channels by phenol derivatives
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
EP1482917B1 (en) * 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
ATE533472T1 (de) * 2002-08-14 2011-12-15 Gw Pharma Ltd Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
WO2006024958A2 (en) * 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20100158973A1 (en) 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
US9956182B2 (en) 2013-05-02 2018-05-01 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20180296521A1 (en) * 2015-10-16 2018-10-18 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
CA3077624A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
EP3534893A1 (en) 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
EP3592346A4 (en) 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
JP6893012B2 (ja) * 2017-07-18 2021-06-23 徳義制薬有限公司Ｄｅｙｉ Ｐｈａｒｍａｒｍａｃｅｕｔｉｃａｌ Ｌｔｄ． 肺高血圧症の治療におけるカンナビジオールの応用
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
WO2020081513A1 (en) * 2018-10-16 2020-04-23 Systamedic Inc. Novel compositions for the treatment of inflammatory diseases
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
AU2019424226B2 (en) * 2019-01-24 2023-06-29 Hanyi Bio-Technology Company Ltd. Use of geranylflavone A in preparation of drug for promoting healing of wounds
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
EP3923915A4 (en) * 2019-02-11 2023-03-22 John Robert Chancey METHODS OF PREPARATION AND USE OF PHYTOCANNABINOIDS IN A COMPLEX WITH A PROTEIN, PEPTIDE, AMINO ACID, POLYSACCHARIDE, DISACCHARIDE OR MONOSACCHARIDE
WO2020223510A1 (en) * 2019-04-30 2020-11-05 Greenway Herbal Products, Llc Cannabinoid compositions and methods of using
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US20230128114A1 (en) * 2020-04-02 2023-04-27 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CA3182152A1 (en) * 2020-05-11 2021-11-18 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
US20230201284A1 (en) * 2020-05-11 2023-06-29 Add Advanced Drug Delivery Technologies Ltd. Uses and Formulations of Cannabinoids
AU2021386606A1 (en) 2020-11-24 2023-06-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity
US20240325312A1 (en) * 2021-07-15 2024-10-03 Incannex Healthcare Limited Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule
EP4436559A4 (en) * 2021-11-27 2025-04-02 Miralogx LLC SYNTHETIC CANNABINOID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
CA3244798A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa COMPOUNDS AND COMPOSITIONS AGAINST NEURODEGENERATIVE DISEASES
AU2023321655A1 (en) 2022-08-12 2025-02-13 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025259202A1 (en) * 2024-06-12 2025-12-18 Chiang Mai University A method of reprogramming human somatic cells and reprogrammed cells derived thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
JP2002511411A (ja) 2002-04-16
ATE288749T1 (de) 2005-02-15
ES2241277T3 (es) 2005-10-16
EP1071417A1 (en) 2001-01-31
US6410588B1 (en) 2002-06-25
DE69923671D1 (de) 2005-03-17
IL138979A0 (en) 2001-11-25
WO1999052524A1 (en) 1999-10-21
AU3436199A (en) 1999-11-01
DK1071417T3 (da) 2005-06-13
CA2328368A1 (en) 1999-10-21
EP1071417B1 (en) 2005-02-09
AU757945B2 (en) 2003-03-13
CA2328368C (en) 2009-03-31
DE69923671T2 (de) 2006-03-16

Similar Documents

Publication Publication Date Title
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
BR9910251A (pt) Estimulação hematopoiética
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
MY138883A (en) Use of asiatic acid for treatment of cencer
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU6178198A (en) Method of treating a tumor
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
GB9621630D0 (en) Treatment of skin disorders
CA2408541A1 (en) Treating eczema and/or psoriasis
ES2192840T3 (es) Laxante osmotico no fermentado para tratar y prevenir cancer colorrectal.
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
BG101126A (en) The use of muramylpeptide compounds
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE69905602D1 (de) Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
NO20012569L (no) Anvendelse av aryl-substituerte syklobutylalkylaminer for behandling av urininkontinens
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
IL139303A0 (en) Treatment of arthritis and other similar conditions
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
MD916G2 (ro) Unguent pentru tratamentul afecţiunilor dentare
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)